CareLit Fachartikel
Effect of HTI–286 and CCI–779 alone and in combination on hepatic tumour cell proliferation
Y Vashist, C Tiffon, C Stoupis, C Redaelli · Zeitschrift für Gastroenterologie · 2006 · Heft 01
Dokument
1102859
CareLit-ID
Jahr
2006
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Overall survival in general is poor in HCC patients as most present with condition of advanced disease when surgical resection or transplantation is not possible anymore. Lack of conventional systemic chemotherapy is a non-acceptable circumstance. HTI–286 (HTI) is a new synthetic analogue of the tripeptide Hemiasterlin with antimicrotubule properties. It circumvents the P-glycoprotein mediated resistance in tumour cells. CCI–779 is known to inhibit tumour growth by antiangiogenesis. Here we studied the inhibitory effect of HTI and CCI–779 alone or in combination on hepatic tumour cell proliferation in vitro and…
Schlagworte
CCI-779 tumour proliferation
HCC
HTI-286
Bromodeoxyuridine
Germany
Transplantation
Tumor
Zeitschrift für Gastroenterologie
